Added riboflavin,
does it really help with Hemoglobin increase in anemic pregnant women receiving iron and folate?
research showsHuman studies adding B2 to iron and folate in anemic pregnant women were identified. However, the precise Hb increment and precision for B2 alone could not be separately verified from currently accessible material, giving C·46. This is not treated as no research or no effect, nor generalized to treatment of all anemia.
ads claimAdvertising and mechanistic claims were not used as grade bonuses or direct clinical evidence.
Four separate assessment dimensions
| Effect direction and size | Human studies adding B2 to iron and folate in anemic pregnant women were identified. However, the precise Hb increment and precision for B2 alone could not be separately verified from currently accessible material, giving C·46. This is not treated as no research or no effect, nor generalized to treatment of all anemia. |
|---|---|
| Evidence certainty | Hb is a surrogate (S). The decisive randomized trial supporting the principal contrast is R1; unverified funding is I1 under precedent 29. The B2-only treatment magnitude is not currently verified (EX, CX), and short duration gives B1. The supplied calculator returns C, with 0 strength axes giving the fixed score of 46. |
| Applicability | Pregnant women selected for anemia by Hb; not all confirmed to have iron-deficiency anemia |
| Safety | The existence of a pregnancy study does not establish safety across doses and formulations. Arm-level adverse-event denominators and long-term maternal/fetal outcomes were not verified in the accessed material. This is not advice to stop shared iron–folate treatment or replace it with B2. |
Not official GRADE or treatment-success probability; ? has no score.
Useful facts when choosing a product
- The target question concerns oral supplementation. Ma’s abstract specifies supplement amounts and arms but not an explicit route or detailed dosage form, so the actual study route is not filled in as a verified fact. The oral question and unconfirmed observed route are separated in structured fields.
Chamgap Semantic Classification Code
Permanent code issued
S.riboflavin.oral-addon.anemic-pregnancy-hemoglobin.increase.addonSupplements > Added riboflavin > Oral add-on > Hemoglobin in anemic pregnancy > Increase claim > Added to common iron and folate
Technically bound to the current-value claim boundary fixed by ChatGPT. Unconfirmed dose, duration, study details, and evidence grade remain in verdict fields and revision history rather than the permanent semantic code. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Added riboflavin (vitamin B2) |
| Source or part used | Synthetic/fermentation/other production origin unconfirmed; plant-part classification not applicable |
| Formulation or processing | Supplement comparison adding B2 alone; detailed dosage form/release profile unconfirmed in the decisive abstract |
| Route | Oral (page question; see observed_evidence for study-route verification) |
| Dose | Principal question: B2 1.0 mg/day added; 5 mg from another study not pooled |
| Duration | Principal question: 2 months; longer-term/postpartum persistence unconfirmed |
| Population | Pregnant women selected for anemia by Hb; not all confirmed to have iron-deficiency anemia |
| Effect or condition | Hemoglobin increase in anemic pregnant women receiving iron and folate |
| Primary endpoint | Between-group difference in blood Hb change; distinct from anemia prevalence and combined-nutrient effects |
| Comparator | Matched iron 60 mg/day and folic acid 400 μg/day; excludes vitamin A add-on arms |
| Duplicate-detection key | riboflavin-addon|oral|1mg-day|2months|anemic-pregnancy-on-iron-folate|hemoglobin-change|iron-60mg-folate-400ug-background |
What the research actually shows
The principal contrast is IFB versus IF in Ma’s trial, isolating the arm that added only B2 to shared iron and folate. The abstract’s 5.4±1.1 g/L belongs to IFAB versus IF, which added vitamin A as well as B2, and is not adopted as the B2-only increment. Hb-defined anemia is not assumed to establish iron deficiency in every participant.
Why this is classified as C (46)
Hb is a surrogate (S). The decisive randomized trial supporting the principal contrast is R1; unverified funding is I1 under precedent 29. The B2-only treatment magnitude is not currently verified (EX, CX), and short duration gives B1. The supplied calculator returns C, with 0 strength axes giving the fixed score of 46.
Counterpoint. Suprapto’s study used alternating allocation and excluded participants from analysis. Its significant abstract comparison was the B2 arm versus the vitamin A arm, not confirmed B2 benefit versus iron–folate alone. RIBOFEM’s low-B2 healthy-woman population and sample-size assumptions are not used as observed treatment effects for the present anemia question.
Rejudgment record. Human studies adding B2 to iron and folate in anemic pregnant women were identified. However, the precise Hb increment and precision for B2 alone could not be separately verified from currently accessible material, giving C·46. This is not treated as no research or no effect, nor generalized to treatment of all anemia. — Hb is a surrogate (S). The decisive randomized trial supporting the principal contrast is R1; unverified funding is I1 under precedent 29. The B2-only treatment magnitude is not currently verified (EX, CX), and short duration gives B1. The supplied calculator returns C, with 0 strength axes giving the fixed score of 46.
| Endpoint | S | Surrogate marker - laboratory or imaging measures Case application: S: Hb laboratory endpoint |
| Replication | R1 | Single confirmatory trial Case application: R1: decisive Ma contrast; different-dose alternating-allocation study not verified independent replication of the exact contrast |
| Independence | I1 | Mixed funding sources Case application: I1: funding not obtained, precedent 29 |
| Effect size | EX | The clinical size of the effect could not be judged Case application: EX: IFB–IF Hb magnitude not verified; combined vitamin A+B2 contrast excluded |
| Precision | CX | No pooled confidence interval could be confirmed Case application: CX: IFB–IF CI not verified |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Review performed and remaining limitations
Complete cause-specific classification of Hb-defined anemia unconfirmed Actual route and detailed dosage form not stated in the decisive accessed abstract IFB–IF Hb difference, dispersion, interval and analysis denominator unconfirmed Full text could not be obtained through the linked source Native databases worldwide were not exhaustively searched; the current judgment is published with that limitation.
Search scope and limitations. tasks/R01-006/search_log.json
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Ma et al. — retinol/riboflavin added to iron and folate in anemic pregnant women (2008) | Randomized double-blind four-arm trial; B2 add-on contrast IFB–IF | 366 assigned overall; IFB 91, IF 93; Hb analysis denominator unconfirmed | Unconfirmed or not used in this page grade | Hb and anemia prevalence in anemic pregnant women; registered primary designation unverified | IFB–IF Hb magnitude and dispersion for B2 alone remain unconfirmed; the vitamin A+B2 combination estimate is not transferred | Decisive result with explicitly unconfirmed route details |
| Suprapto et al. — riboflavin added to iron–folate in anemic pregnant women (2002) | Alternating allocation; not asserted to be randomized | Only verified denominators are recorded in numeric_evidence.json; assignment totals are not substituted for unknown endpoint analysis counts. | Unconfirmed or not used in this page grade | Hb in anemic pregnant women; alternating allocation and multiple comparisons | The study alternately allocated 103 pregnant participants. Riboflavin (B2) was 5 mg for 60 days; 19 participants (reported 18.4%) were excluded from analysis. | Indirect contextual evidence |
| RIBOFEM protocol — riboflavin status and hematology in young women | Excluded: different population and protocol, not results | Only verified denominators are recorded in numeric_evidence.json; assignment totals are not substituted for unknown endpoint analysis counts. | Unconfirmed or not used in this page grade | Hematology protocol in healthy women with low B2 status, not observed results | RIBOFEM recruited healthy young women with low B2 status. A Hb difference used for sample-size planning is not an observed treatment result. | Excluded: different population and protocol, not results |
| Correcting marginal riboflavin deficiency and hematologic status in young UK women (2011) | Same-trial candidate; outcome details not verified | Only verified denominators are recorded in numeric_evidence.json; assignment totals are not substituted for unknown endpoint analysis counts. | Unconfirmed or not used in this page grade | Hematology result paper in healthy women; no current full-text effect value adopted | Prior bibliography/access record reused; no unverified effect estimate adopted. | Same-trial candidate; outcome details not verified |
Receipt — 4 References
Evidence access cutoff: 2026-09-15. Each citation states its actual access level (full-text transcription, abstract, index, or other) and remaining limitations. Bibliographic checking does not certify the study results or treatment efficacy.
Technical integration by: Codex · Evidence date: 2026-09-15 · Corrections: 2
Correction log — 2
Corrections applied to this verdict, in chronological order. Changes are logged, not erased.
- 2026-09-15 · current_value_initial_publication — 5.4±1.1 g/L was excluded as an isolated B2 effect. The unspecified dispersion type was not filled in as SD or SE.
- 2026-09-15 · current_value_initial_publication — Alternating allocation was not labeled randomization; a sample-size assumption was not used as an observed Hb increase.
Cite this verdict
[Chamgap] Added riboflavin (vitamin B2) × Hemoglobin increase in anemic pregnant women receiving iron and folate — Evidence Grade C·46. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/energy/riboflavin-addon-anemic-pregnancy-hemoglobin/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.